The funds will support clinical work in multiple sclerosis (MS), inflammatory bowel disease (IBD) and allergic/immune-mediated disorders. (See BioWorld Today, April 8, 2013.) The pricing hits pretty close to the $86.3 million target set when the company filed for its offering only a month ago...Senesco is advancing its ongoing Phase Ib/IIa study of SNS01-T, an approach to cancer therapy designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma and mantle cell and diffuse
By Catherine Shaffer | BioWorld Today | Friday, May 10, 2013
Data demonstrated that EBI-005 was safe and well tolerated in both preclinical testing and in a clinical Phase Ia study in healthy volunteers...These data led to Eleven's Phase Ib clinical study of EBI-005 in subjects with dry eye disease, with top-line data from the Phase Ib study expected in the second half of 2013...SymBio Pharmaceuticals Ltd., of Tokyo, said it completed patient enrollment in its Phase II study of Treakisym (bendamustine hydrochloride, SyB L-0501) in front-line low-grade non
The NH004-3 clinical trial is a double-blind, placebo-controlled, randomized, crossover, multicenter study comparing NH004 and placebo thin films in Parkinson's disease patient complaining of sialorrhea...Senesco Technologies Inc., of Bridgewater, N.J., said the Data Review Committee (DRC) for its SNS01-T trial in multiple myeloma and non-Hodgkin's B-cell lymphoma approved initiating cohort 3 and escalating the SNS01-T dose level fourfold to 0.2 mg/Kg
The funding allowed ReXceptor to enter a formal partnership with C2N Diagnostics, which will assist the company with the initiation and coordination of the clinical trial of an AD program licensed from Case Western's Technology Transfer Office and based on discoveries that bexarotene, a medication sold at Targretin for cutaneous T-cell lymphomas, reversed AD symptoms in mice within 72 hours of a single dose of treatment.
By Jennifer Boggs | BioWorld Today | Monday, April 29, 2013
The primary objectives include the evaluation of adverse events and a six-month clinical response...Senesco Technologies Inc., of Bridgewater, N.J., completed the second cohort of its Phase Ib/IIa trial of SNS01-T. Two multiple myeloma patients and one diffuse large B-cell lymphoma patient have completed the study
Shape Pharmaceuticals Inc., of Cambridge, Mass., said SHP-141, its topical histone deacetylase inhibitor in development for cutaneous T-cell lymphoma (CTCL), is being tested in a Phase Ib trial designed to evaluate escalating doses in patients with Stage Ia, Ib or IIa CTCL...Also, 93 percent of people in that dose group showed no clinical symptoms of influenza after three days of treatment, compared to 41 percent of people in the placebo group
Repros Therapeutics Inc., of The Woodlands, Texas, provided a revised date for expected clinical results from the first pivotal trial, ZA-301, of Androxel (enclomiphene) in secondary hypogonadism, with data expected in the third quarter rather than the second quarter...The safety findings from the pivotal Phase II trial of belinostat, a pan-histone deacetylase inhibitor, featured in an oral presentation at the T-Cell Lymphoma Forum in San Francisco
Seattle Genetics Inc., of Bothell, Wash., and Millennium: The Takeda Oncology Co., of Cambridge, Mass., reported the start of a global Phase III trial evaluating Adcetris (brentuximab vedotin), an antibody-drug conjugate directed to CD30, in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas...Sirtex Medical Ltd
Spectrum Pharmaceuticals Inc., of Henderson, Nev., presented clinical data at the recent American Society of Hematology meeting in Atlanta for cancer drug Zevalin (yttrium-90-ibritumomab tiuxetan), including results from a Phase II study showing that Zevalin plus BEAM chemotherapy (carmustine, etoposide, cytarabine and melphalan) prior to autologous stem cell transplantation in refractory non-Hodgkin's diffuse large B-cell lymphoma produced a two-year overall survival rate of 65 percent and a
Data also indicated rapid onset of activity, with clinical activity reported for 16 of 19 responders occurring within the first two cycles of treatment...OncoSec plans to use the proceeds to fund clinical trials and research and development and for other corporate purposes...The company plans to use the proceeds to fund research and development, clinical trials and for other corporate purposes.
By Marie Powers | BioWorld Today | Friday, December 14, 2012
Data demonstrated that patients with established atrial fibrillation (AF) receiving Gencaro in the trial had improvements in heart failure clinical endpoints, and those receiving Gencaro were more likely to achieve ventricular rate control...The first trial in aggressive B-cell lymphomas showed that patients had an overall response rate of 98 percent, and one-year progression-free survival of 73 percent
BCI-838 showed a favorable safety profile, with no treatment-related trends in clinical laboratory results, vital sign measurements, 12 lead ECG results or physical examination findings, and the drug was well tolerated up to the dose levels predicted for efficacy...PNT2258 targets Bcl-2-driven tumors such as diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia
Senesco Technologies Inc., of Bridgewater, N.J., said it expanded its clinical trial of SNS01-T to include diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) patients
Inc.'s Zolinza (vorinostat) and Celgene Corp.'s Istodax (romidepsin) in peripheral T-cell lymphoma...The company laid groundwork for clinical trials in advance of the financing and plans to begin a "very substantial" randomized Phase II study in the U.S...Novelos plans to use the proceeds to complete an in-house clinical-stage manufacturing facility for its small-molecule, broad-spectrum, cancer-targeted imaging agent I-124-CLR1404 (LIGHT
By Marie Powers | BioWorld Today | Tuesday, November 6, 2012
Alexion Pharmaceuticals Inc., of Cheshire, Conn., said researchers presented data from an open-label Phase II study in 14 patients with severe, relapsing neuromyelitis optica (NMO), showing that Soliris (eculizumab) met its primary endpoint with high degrees of clinical and statistical significance...The positive clinical effects of the twice-daily dose of the drug relative to placebo were observed in a variety of standard psoriasis assessment parameters, with the responses accumulating over the 24
In 2011, the FDA gave accelerated approval to Adcetris for Hodgkin lymphoma after the failure of either autologous stem cell transplant or at least two multi-agent chemotherapy regimens in transplant-ineligible patients and for systemic anaplastic large cell lymphoma after the failure of at least one multi-agent chemotherapy regimen. (See BioWorld Today, Aug. 22, 2011...Vertex Pharmaceuticals Inc., of Cambridge, Mass., and collaborator Alios BioPharma Inc., of South San Francisco, reported results
Topotarget A/S, of Copenhagen, Denmark, reported preliminary clinical results for a trial of belinostat for relapsed and refractory peripheral T-cell lymphoma
Imprimis Pharmaceuticals Inc., of Solana Beach, Calif., said it started a clinical trial testing Impracor, a topical cream designed to deliver ketoprofen...Spectrum Pharmaceuticals Inc., of Henderson, Nev., said it started enrolling patients in its Phase III ZEST (Zevalin Evaluation as Sequential Therapy) trial testing Zevalin (ibritumomab tiuxetan) for intravenous use for first-line consolidation of patients with diffuse large B-cell lymphoma who achieved remission following R-CHOP (rituximab
Net proceeds from the offering will be funneled into clinical development of cancer candidates IPI-145 and retaspimycin...Net proceeds of about $361.9 million will support clinical trials, research and development and other corporate purposes...The funds will be used as working capital to support clinical development of the company's products, including therapies for men's health, female sexual health and respiratory disorders.
By Catherine Shaffer | BioWorld Today | Friday, August 10, 2012
Spectrum Pharmaceuticals Inc., of Henderson, Nev., said data published in the Journal of Clinical Oncology showed first-line consolidation with Zevalin (ibritumomab tiuxetan) injection in patients with mantle-cell lymphoma, following initial therapy consisting of Rituxan (rituximab, Biogen Idec Inc. and Roche AG) with cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP) given for four courses, was well tolerated and improved overall response rate from 68 percent after RCHOP to 82
The funds will support clinical work in multiple sclerosis (MS), inflammatory bowel disease (IBD) and allergic/immune-mediated disorders. (See BioWorld Today, April 8, 2013.) The pricing hits pretty close to the $86.3 million target set when the company filed for its offering only a month ago...Senesco is advancing its ongoing Phase Ib/IIa study of SNS01-T, an approach to cancer therapy designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma and mantle cell and diffuse